Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
Leukemia|May 9, 2020
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trialGerald G Wulf, Bettina Altmann, Marita Ziepert, et al.Blood|April 19, 2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyEmmanuel Bachy, Matthew J Maurer, Thomas M Habermann, et al.Leukemia|September 16, 2020
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemiaRémi Letestu, Abdelmalek Dahmani, Marouane Boubaya, et al.Haematologica|May 5, 2018
Natural history of GATA2 deficiency in a survey of 79 French and Belgian patientsJean Donadieu, Marie Lamant, Claire Fieschi, et al.Blood|January 25, 2020
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifierCecilia Carpio, Reda Bouabdallah, Loïc Ysebaert, et al.Clinical Lymphoma, Myeloma & Leukemia|January 26, 2022
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL StudyMichael Schuster, Josée Zijlstra, Rene-Olivier Casasnovas, et al.Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.The Lancet. Haematology|June 27, 2020
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialNagesh Kalakonda, Marie Maerevoet, Federica Cavallo, et al.The New England Journal of Medicine|November 9, 2007
Chemotherapy plus involved-field radiation in early-stage Hodgkin's diseaseChristophe Fermé, Houchingue Eghbali, Jacobus H Meerwaldt, et al.Pageof 9